Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT00768755. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Randomized Phase 2 Study Of Cisplatin/Pemetrexed With Or Without Axitinib (AG-013736) As First-Line Treatment For Patients With Non-Squamous Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Study identification
- NCT ID
- NCT00768755
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Enrollment
- 180 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 2009 (Type not available)
- Primary completion
- Mar 2011 (Actual)
- Completion
- Mar 2012 (Actual)
- Last update posted
- Oct 28, 2015
2009 – 2012
United States locations
- U.S. sites
- 12
- U.S. states
- 5
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pfizer Investigational Site | Huntsville | Alabama | 35805 | — |
| Pfizer Investigational Site | Atlanta | Georgia | 30341 | — |
| Pfizer Investigational Site | Decatur | Georgia | 30033 | — |
| Pfizer Investigational Site | Macon | Georgia | 31217 | — |
| Pfizer Investigational Site | Marietta | Georgia | 30060 | — |
| Pfizer Investigational Site | Sandy Springs | Georgia | 30342 | — |
| Pfizer Investigational Site | Bloomington | Illinois | 61701 | — |
| Pfizer Investigational Site | Peoria | Illinois | 61615 | — |
| Pfizer Investigational Site | Hershey | Pennsylvania | 17033-0850 | — |
| Pfizer Investigational Site | West Reading | Pennsylvania | 19611 | — |
| Pfizer Investigational Site | East Providence | Rhode Island | 02914 | — |
| Pfizer Investigational Site | East Providence | Rhode Island | 02915 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 40 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00768755, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 28, 2015 · Synced Oct 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00768755 live on ClinicalTrials.gov.